Frequencies of the respective chromosomal aberrations
| . | Group 1: AL without MM I, n = 75 . | Group 2: AL plus MM I, n = 10 . | Group 3: MGUS, n = 127 . | Group 4: MM I, n = 19 . |
|---|---|---|---|---|
| IgH translocations | ||||
| IgH breakapart | 37/51 (73) | 4/7 (57) | 39/66 (59) | 10/12 (83) |
| t(11;14) | 35/75 (47) | 3/10 (30) | 33/127 (26) | 5/19 (26) |
| t(4;14) | 2/75 (3) | 1/10 (10) | 12/127 (9) | 5/19 (26) |
| t(14;16) | 2/54 (4) | 0/7 (0) | 2/74 (3) | 0/12 (0) |
| IgH rearrangement with unknown translocation partner | 11/51 (22) | 2/7 (29) | 13/66 (20) | 1/11 (9) |
| Gains | ||||
| 1q21 | 14/74 (19) | 5/10 (50) | 16/109 (15) | 9/17 (53) |
| 11q23 | 25/75 (33) | 4/10 (40) | 42/126 (33) | 6/19 (32) |
| 19q13 | 8/55 (15) | 3/8 (38) | 20/79 (25) | 4/13 (31) |
| Deletions | ||||
| 8p21 | 4/55 (7) | 1/8 (13) | 5/77 (6) | 3/12 (25) |
| 13q14 | 23/75 (31) | 4/10 (40) | 39/127 (31) | 10/19 (53) |
| 17p13 | 0/74 (0) | 1/10 (10) | 5/124 (4) | 0/19 (0) |
| . | Group 1: AL without MM I, n = 75 . | Group 2: AL plus MM I, n = 10 . | Group 3: MGUS, n = 127 . | Group 4: MM I, n = 19 . |
|---|---|---|---|---|
| IgH translocations | ||||
| IgH breakapart | 37/51 (73) | 4/7 (57) | 39/66 (59) | 10/12 (83) |
| t(11;14) | 35/75 (47) | 3/10 (30) | 33/127 (26) | 5/19 (26) |
| t(4;14) | 2/75 (3) | 1/10 (10) | 12/127 (9) | 5/19 (26) |
| t(14;16) | 2/54 (4) | 0/7 (0) | 2/74 (3) | 0/12 (0) |
| IgH rearrangement with unknown translocation partner | 11/51 (22) | 2/7 (29) | 13/66 (20) | 1/11 (9) |
| Gains | ||||
| 1q21 | 14/74 (19) | 5/10 (50) | 16/109 (15) | 9/17 (53) |
| 11q23 | 25/75 (33) | 4/10 (40) | 42/126 (33) | 6/19 (32) |
| 19q13 | 8/55 (15) | 3/8 (38) | 20/79 (25) | 4/13 (31) |
| Deletions | ||||
| 8p21 | 4/55 (7) | 1/8 (13) | 5/77 (6) | 3/12 (25) |
| 13q14 | 23/75 (31) | 4/10 (40) | 39/127 (31) | 10/19 (53) |
| 17p13 | 0/74 (0) | 1/10 (10) | 5/124 (4) | 0/19 (0) |
Frequencies [no./N(%)]of the respective CA specified according to the four patient groups are given. Whereas the AL amyloidosis group displays the highest frequency of t(11;14), the MM I group is characterized by a higher frequency of gain 1q21. The determination of the IgH breakapart frequency is based on 136 patients, whereas the subgroups t(11;14), t(4;14), and t(14;16) are based on a larger cohort of 231, 231, and 147 patients, respectively. Due to the different sizes of the patient groups, the sum of the single translocations does not correspond exactly to the overall IgH breakapart frequency.